For example, the poor expression of DC-SIGN and CD206 on circulating cDC2s in melanoma patients questions the use of these CLRs for therapeutic exploitation, and emphasizes the need to perform pre-clinical studies on in situ DCs and not in vitro made DCs, which display a different CLR expression pattern. This evidence concerns the gene LARS1 and melanoma.